Songlin Peng

Dr. Songlin Peng


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DYDianbo Yao
Dianbo Yao
SPSonglin Peng
Songlin Peng
CDChaoliu Dai
Chaoliu Dai
Background: Mesenchymal–epithelial transition (MET) is now suggested to participate in the process of metastatic tumor formation. However, in hepatocellular carcinoma (HCC) the process is still not well revealed. Methods: Paraffin-embedded tissue samples were obtained from 13 patients with HCC in Shengjing Hospital of China Medical University. The expression of E-cadherin, Fibronectin, N-cadherin, Vimentin, Hepatocyte nuclear factor 4alpha (HNF4alpha), Snail and Slug was assessed in primary tumors and their corresponding metastases by immunohistochemical staining. Next, the expression of HNF4alpha and E-cadherin in four HCC cell lines was examined. Furthermore, SK-Hep-1 cells were transfected with human HNF4alpha expression vector, and the change of E-cadherin expression was assessed. Results: 45.2% (14/31) of the lesions in the metastases showed increased E-cadherin expression compared with the primaries, suggesting the possible occurrence of MET in metastatic tumor formation of HCC, as re-expression of E-cadherin is proposed to be the important hallmark of MET. The occurrence of MET was also confirmed by the reduced expression of Fibronectin (54.8%, 17/31), N-cadherin (38.7%, 12/31) and Vimentin (61.3%, 19/31) in the metastases. 45.2% (14/31) of the lesions in the metastases also showed increased HNF4alpha expression, and 67.7% (21/31) and 48.4% (15/31) of metastases showed decreased Snail and Slug expression respectively. Statistical results showed that the expression of HNF4alpha was positively related with that of E-cadherin, and negatively correlated with that of Snail, Slug and Fibronectin, suggesting that the expression change of the MET markers in the metastatic lesions might be associated with HNF4alpha. Among the four HCC cell lines, both HNF4alpha and E-cadherin expressed high in Hep3B and Huh-7 cells, but low in SK-Hep-1 and Bel-7402 cells. Furthermore, the expression of E-cadherin increased accordingly when SK-Hep-1 cells were transfected with human HNF4alpha expression vector, further confirming the role of HNF4alpha in the regulation of E-cadherin expression. Conclusions: Our clinical observations and experimental data indicate that HNF4alpha might play a crucial role in the metastatic tumor formation of HCC, and the mechanism may be related with the process of phenotype transition.

6 May 2024 in Heliyon
Verified
Journal Article
Open access
YLYan Lu
Yan Lu
FXFei Xing
Fei Xing
SPSonglin Peng
Songlin Peng
The CXCL12-CXCR4/CXCR7 axis is garnering growing attention. But the comprehension of its function in the progression of HCC remains controversial. The purpose of this study was to investigate the effects of CXCL12 and its receptor on the prognosis of patients with viral hepatitis-associated HCC after hepatectomy. A total of 86 patients had been enrolled who had undergone hepatectomy for HCC and followed up to July 31, 2019, and their clinicopathological and follow-up data were recorded. Tumor and peritumoral tissues were obtained to detect the expression of CXCL12, CXCR4, and CXCR7 using immunohistochemistry. Real-time polymerase chain reaction was utilized to detect hepatitis B or C virus loads, while survival analysis was performed using the Kaplan–Meier method. Furthermore, the Cox proportional hazards regression model was employed to analyze the factors affecting the prognosis. The results revealed that the CXCL12, CXCR4, and CXCR7 expression in tumor tissues was lower than in the corresponding non-tumor tissues in 20.93 %, 22.09 %, and 23.26 % of the patients, respectively, and that only CXCL12 was found to be related to the extrahepatic invasion of HCC. The survival analysis and Cox regression showed that only CXCL12 was associated with the postoperative survival of patients with HCC, and that it was an independent prognostic risk factor in the CXCL12-CXCR4/CXCR7 axis. The CXCL12low group represented shorter progression-free survival and lower overall survival rates. However, the subgroup analysis displayed that the survival difference associated with CXCL12 was only manifested in patients with higher expression of CXCR4 or CXCR7 in HCC, as compared to the surrounding tissues. Our findings suggest that, when assessing the prognostic significance of CXCL12 in HCC, it is essential to consider the expression level of its receptor. Nevertheless, CXCL12 can potentially serve as a promising prognostic marker for HCC.

1 January 2019 in International Journal of Hyperthermia
Verified
Journal Article
Open access
TJTianqiang Jin
Tianqiang Jin
XLXiaolin Liu
Xiaolin Liu
CDChaoliu Dai
Chaoliu Dai
CJChangjun Jia
Changjun Jia
SPSonglin Peng
Songlin Peng
FXFeng Xu
Feng Xu
Purpose: In this study, we evaluated the efficacy of microwave ablation-assisted laparoscopic hepatectomy (MLH) for the management of hepatocellular carcinoma (HCC) in cirrhotic patients. Methods: Data from HCC patients with liver cirrhosis who underwent laparoscopic hepatectomy (LH) or MLH in Shengjing Hospital (Shenyang, China) were retrospectively analyzed from January 2013 to June 2017. The demographic characteristics, clinical features, intraoperative parameters and surgical outcomes were analyzed and compared. Propensity scores matching (PSM) analysis was used to minimize bias. Results: A total of 54 patients were enrolled in the MLH group and 39 patients in the LH group. Following 1:1 matching by PSM analysis, 26 patients were selected from each group. Compared to the LH group, patients in the MLH group had significantly decreased intraoperative bleeding (48.0 vs. 203.9 ml, p < .0001) and reduced demand for hepatic inflow occlusion (0 vs. 6, p = .009). No significant difference was observed in average operation time (155.7 vs. 148.5 min) and postoperative hospitalization time (8.3 vs. 9.3 d) between the MLH and LH groups. Similarly, the 1-year and 3-year recurrence-free survival (RFS) rates as well as the 1-year and 3-year overall survival (OS) rates of the MLH and LH groups were not significantly different (83.1 vs. 82.4% and 64.6 vs. 36.6% as well as 100 vs. 95.8% and 93.8 vs. 59.1%, respectively: p > .05). Conclusions: MLH significantly decreased intraoperative bleeding and reduced the need for hepatic occlusion without compromising the surgical outcome. Therefore, microwave ablation could be a valuable tool for LH in HCC patients with cirrhosis.

28 May 2025 in Clinical Immunology
Verified
Journal Article
Closed access
WQWei Qin
Wei Qin
XWXiaoying Wu
Xiaoying Wu
QXQiongyuan Xu
Qiongyuan Xu
MDMin Deng
Min Deng
XLXiangling Lin
Xiangling Lin
SPSonglin Peng
Songlin Peng

22 April 2026 in Cancer Reports
Verified
Journal Article
Open access
KZKaiwen Zhong
Kaiwen Zhong
XWXiaoying Wu
Xiaoying Wu
XLXiangling Lin
Xiangling Lin
MXMaoyun Xie
Maoyun Xie
Min DENGMin DENG
Min DENG
SPSonglin Peng
Songlin Peng
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, with high rates of mortality and drug resistance. Carbohydrate antigen 19‐9 (CA19‐9) is a tumor biomarker for diagnosis and prognosis in PDAC. However, elevated alpha‐fetoprotein (AFP) is exceedingly rare in the PDAC patient. Case Presentation: Herein, we describe a 67‐year‐old woman who presented with elevated AFP before the diagnosis of PDAC. In March 2025, this patient who had elevated AFP and CA19‐9 levels and was presenting with jaundice, was diagnosed with PDAC. Subsequently, she underwent pancreaticoduodenectomy, partial resection of the superior mesenteric vein (SMV), and SMV reconstruction. After radical resection (R0), the levels of AFP and CA19‐9 were significantly decreased. Next, she was treated with adjuvant chemotherapy (gemcitabine plus capecitabine). After four cycles of treatment, the patient presented with diarrhea, weight loss, poor nutritional status, and other signs of poor tolerance to chemotherapy. Thus, the regimen was changed to pembrolizumab plus trametinib. Hepatic recurrence was detected at the 7‐month follow‐up. At 11 months after surgery, the patient developed a biliary tract infection and obstructive jaundice, and ultimately died. Conclusions: This case demonstrates that AFP may be a potential biomarker for PDAC, especially in the CA19‐9‐negative PDAC patient.